A phase I study of CCI-779 [temsirolimus] in combination with imatinib mesylate in chronic myelogenous leukemia

Trial Profile

A phase I study of CCI-779 [temsirolimus] in combination with imatinib mesylate in chronic myelogenous leukemia

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2013

At a glance

  • Drugs Imatinib (Primary) ; Temsirolimus (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 27 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Aug 2010 New source identified and integrated (Moores UCSD Cancer Center).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top